Adicet Bio, Inc. (ACET) stock
ACETNasdaqPharmaceutical PreparationsFiscal year ends December 26
$2.50−0.28 (-10.07%)
Close on Nov 18, 2026Market cap $23.40MP/E –Yield –
Adicet Bio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Adicet Bio's free cash flow for the twelve months ending Jun 30, 2026 was -$84.97M. For fiscal 2025 it was -$96.98M. The highest annual figure on record is -$11.03M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$96.98M | – |
| FY2024 | Dec 31, 2024 | -$93.50M | – |
| FY2023 | Dec 31, 2023 | -$98.18M | – |
| FY2022 | Dec 31, 2022 | -$61.55M | – |
| FY2021 | Dec 31, 2021 | -$64.10M | – |
| FY2020 | Dec 31, 2020 | -$42.54M | – |
| FY2019 | Dec 31, 2019 | -$28.95M | – |
| FY2018 | Dec 31, 2018 | -$19.06M | – |
| FY2017 | Dec 31, 2017 | -$11.03M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$20.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.53M | – |
| Q4 FY2025 | Dec 31, 2025 | -$20.90M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.52M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.68M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.89M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$22.41M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.72M | – |
| Q1 FY2024 | Mar 31, 2024 | -$23.09M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$22.14M | – |
| Q2 FY2023 | Jun 30, 2023 | -$26.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.01M | -1865.7% |
| Q4 FY2022 | Dec 31, 2022 | -$25.33M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.14M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.55M | – |
| Q1 FY2022 | Mar 31, 2022 | $1.47M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.52M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.86M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.91M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.80M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.71M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.07M | -260.1% |
| Q2 FY2020 | Jun 30, 2020 | -$12.12M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.65M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.72M | -185.0% |
| Q3 FY2019 | Sep 30, 2019 | $5.04M | – |
| Q2 FY2019 | Jun 30, 2019 | -$14.20M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.07M | – |
| Q4 FY2018 | Dec 31, 2018 | $9.08M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.75M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.81M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.58M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.99M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.85M | – |
See a number that looks wrong?